Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 591

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 591
---
nur, the two-class method and subsequent allocation of loss will not be used when New Semnur is in a net loss position. Thus, and as no dividends or distributions have been declared, the shares of New Semnur Series A Preferred Stock have no impact to the calculations of basic EPS. Further, given the shares of New Semnur Series A Preferred Stock are not legally convertible into shares of New Semnur Common Stock, there will be no incremental changes to the dilutive EPS calculation. |

358

DIRECTORS AND EXECUTIVE OFFICERS OF DENALI References in this section to “Denali,” “we,” “our” or “us” refer to Denali Capital Acquisition Corp. Current Directors and Executive Officers Denali’s current directors and officers are as follows:

| Name                |     | Age* |    |     | Position                             |
| Lei Huang           |     |      | 53 |     | Chief Executive Officer and Director |
| You (“Patrick”) Sun |     |      | 37 |     | Chief Financial Officer              |
| Huifeng Chang       |     |      | 59 |     | Director                             |
| Jim Mao             |     |      | 57 |     | Director                             |
| Kevin Vassily       |     |      | 58 |     | Director                             |

| * | Age as of the date of this proxy statement/prospectus. |

Lei Huang, Chief Executive Officer and Director Mr. Huang has served as a director of Denali and Denali’s Chief Executive Officer since its inception. Mr. Huang has also served as a member of the board of directors of US Tiger since December 2019 and previously served as a director of its parent company, UP Fintech Holding Limited (Nasdaq: TIGR), from November 2020 until June 2022. Since December 2021, Mr. Huang has served as the Chief Executive Officer and has been a member of the board of directors of TradeUP Securities, Inc., a broker/dealer company. He has also been a member of the board of directors of MDL and International Corporation since December 2020. He served as the Chief Executive Officer and was a member of the board of directors of Fortune Rise Acquisition Corporation (Nasdaq: FRLA), a special purpose acquisition company, since its incorporation in January 2021 until December 2022. Prior to joining US Tiger, Mr. Huang was the Chief Executive Officer of Haitong Securities USA LLC